+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Age-Related Macular Degeneration: Epidemiology Forecast to 2028

  • PDF Icon

    Report

  • 46 Pages
  • April 2020
  • Region: Global
  • GlobalData
  • ID: 5017242
Age-Related Macular Degeneration: Epidemiology Forecast to 2028

Summary

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly (National Eye Institution, 2019). AMD is classified into three stages: early AMD, intermediate AMD, and late AMD.

Late AMD is the advanced stage of AMD, which is characterized by the presence of late dry AMD (geographic atrophy) or late wet (neovascular or exudative) AMD (van Leeuwen et al., 2003; Coleman et al., 2008; Korb et al., 2014). According to a meta-analysis of studies conducted before May 2013, the global prevalence of AMD was reported to be 8.69% among adults ages 45–85 years, but the country-specific prevalence can be as high as 30–40% (Augood et al., 2006; Wong et al., 2014). In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual (Hassell, 2006).

In 2018, there were 97,243,455 total prevalent cases of AMD in men and women combined, ages 50 years and older, in the 9MM. China accounted for the majority of these cases with 20,914,288 total prevalent cases, while Australia accounted for the fewest cases with 778,580 cases in 2018. Epidemiologists forecast an increase in the total prevalent cases of AMD to 114,928,241 cases in 2028 in the 9MM at an Annual Growth Rate (AGR) of 1.82% during the forecast period.

Scope

  • The Age-Related Macular Degeneration report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Australia, and China).
  • The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (limited to age 50 years and older).
  • The total and diagnosed prevalent cases of late AMD are further segmented into late dry and late wet AMD.
  • The total prevalent cases of AMD are also segmented by laterality (single eye and both eyes). The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy secondary to late dry AMD in these markets.
  • The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to Buy

The AMD Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
  • Understand magnitude of AMD by stages and laterality.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Age-Related Macular Degeneration: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
3.4.4 Total Prevalent Cases of AMD by Laterality
3.4.5 Total Prevalent Cases of Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
3.4.6 Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
3.5 Epidemiological Forecast for AMD, 2018–2028
3.5.1 Total Prevalent Cases of AMD
3.5.2 Age-Specific Total Prevalent Cases of AMD
3.5.3 Sex-Specific Total Prevalent Cases of AMD
3.5.4 Total Prevalent Cases of AMD by Laterality
3.5.5 Total Prevalent Cases of Early AMD
3.5.6 Total Prevalent Cases of Late AMD
3.5.7 Total Prevalent Cases of Late Dry AMD
3.5.8 Total Prevalent Cases of Late Wet AMD
3.5.9 Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
3.5.10 Diagnosed Prevalent Cases of AMD
3.5.11 Age-Specific Diagnosed Prevalent Cases of AMD
3.5.12 Sex-Specific Diagnosed Prevalent Cases of AMD
3.5.13 Diagnosed Prevalent Cases of Early AMD
3.5.14 Diagnosed Prevalent Cases of Late AMD
3.5.15 Diagnosed Prevalent Cases of Late Dry AMD
3.5.16 Diagnosed Prevalent Cases of Late Wet AMD
3.5.17 Diagnosed Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research – Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About the Publisher
4.5 Contact the Publisher
4.6 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Risk Factors and Comorbidities for AMD
Table 3: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country
List of Figures
Figure 1: 9MM, Total Prevalent Cases of AMD, Both Sexes, Ages =50 Years, 2018 and 2028
Figure 2: 9MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages =50 Years, 2018 and 2028
Figure 3: 9MM, Total Prevalence of AMD, Men and Women, Ages =50 Years, %, 2018
Figure 4: 9MM, Diagnosed Prevalence of AMD, Men and Women, Ages =50 Years, 2018
Figure 5: 9MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
Figure 6: 9MM, Sources Used to Forecast the Total Prevalent Cases of AMD by Laterality
Figure 7: 9MM, Sources Used to Forecast the Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD and Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
Figure 8: 9MM, Total Prevalent Cases of AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 9: 9MM, Total Prevalent Cases of AMDby Age, Both Sexes, N, 2018
Figure 10: 9MM, Total Prevalent Cases of AMD, by Sex, Ages =50 Years, N, 2018
Figure 11: 9MM, Total Prevalent Cases of AMD by Laterality, Ages =50 Years, Both Sexes, N, 2018
Figure 12: 9MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 13: 9MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 14: 9MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 15: 9MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 16: 9MM, Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 17: 9MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 18: 9MM, Diagnosed Prevalent Cases of AMD by Age, Both Sexes, N, 2018
Figure 19: 9MM, Diagnosed Prevalent Cases of AMD, by Sex, Ages =50 Years, N, 2018
Figure 20: 9MM, Diagnosed Prevalent Cases of Early AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 21: 9MM, Diagnosed Prevalent Cases of Late AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 22: 9MM, Diagnosed Prevalent Cases of Late Dry AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 23: 9MM, Diagnosed Prevalent Cases of Late Wet AMD, Both Sexes, Ages =50 Years, N, 2018
Figure 24: 9MM, Diagnosed Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD, Both Sexes, Ages =50 Years, N, 2018